TY - ADVS TI - Monoclonal antibodies in haemato-oncology AU - Cragg, Mark A2 - Waldmann, Herman PY - 2020 DA - 2020/05/31 UR - https://hstalks.com/bs/4266/ AB - Introduction to the development and clinical use of monoclonal antibodies (mAb) in haemato-oncology, Currently approved mAb for treating cancer, Direct targeting antibodies, Rituximab, Fc gamma receptors (FcgR) as key mediators of cellular immunity, Macrophages as key effector cells, B cell deletion as a paradigm for mAb effects, Type I versus Type II antibodies, Obinutuzumab, Hematological malignancies, Immunomodulatory mAb, Combinations between direct targeting and immunomodulatory mAb DB - The Biomedical & Life Sciences Collection SN - 2056-452X ID - 5218 PB - Henry Stewart Talks ER -